Davis Polk advised Morgan Stanley & Co. LLC and Cowen and Company, LLC as joint book-running managers of the several underwriters in connection with the $117.85 million initial public offering of 8,418,000 shares of common stock of Chimerix, Inc., which included 1,098,000 shares from the exercise of the underwriters’ over-allotment option in full. The common stock is listed on the Nasdaq Global Market under the symbol “CMRX.”
Based in Durham, North Carolina, Chimerix, Inc. is a biopharmaceutical company committed to the discovery, development and commercialization of novel, oral antiviral therapeutics that are designed to transform patient care in areas of high unmet medical need. Chimerix, Inc.’s proprietary lipid technology has given rise to two clinical-stage lipid acyclic nucleoside phosphonates, CMX001 and CMX157, which have demonstrated the potential for enhanced activity and safety in convenient, orally administered dosing regimens. Chimerix, Inc. intends to develop CMX001 as the first broad-spectrum antiviral against double-stranded DNA (dsDNA) viruses. Chimerix, Inc.’s second clinical-stage compound, CMX157, is a Phase 1 product candidate for the treatment of HIV and was licensed to Merck, Sharp & Dohme Corp. in 2012.
The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associates Marcel Fausten and Siew Kwok. The intellectual property team included associate Bruce Rose-Innes and law clerk Jansen A. S. Thurmer. Partner Samuel Dimon and associate Omer Harel provided tax advice. The environmental team included counsel Loyti Cheng and law clerk Leah Cowdrey. The executive compensation team included partner Edmond T. FitzGerald and law clerk Beth M. Bates. Counsel Marcie A. Goldstein provided FINRA advice. Sorina Delia Lazar was the legal assistant for the transaction. All members of the Davis Polk team are based in the New York office.
